Viking Therapeutics (VKTX) financial statements
Viking Therapeutics reported revenue of $0 in fiscal 2025.
Net income was -$360M.
The diluted share count rose 592% over the period (dilution).
Income statement
Fiscal years, from Viking Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $9M | $14M | $19M | $24M | $32M | $45M | $54M | $64M | $102M | $345M |
| Selling, general and admin | $5M | $5M | $7M | $9M | $11M | $11M | $16M | $37M | $49M | $48M |
| Operating income | -$14M | -$19M | -$26M | -$33M | -$43M | -$56M | -$70M | -$101M | -$151M | -$393M |
| Pre-tax income | — | — | — | — | — | — | — | -$86M | -$110M | -$360M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $2,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | -$15M | -$21M | -$22M | -$26M | -$39M | -$55M | -$69M | -$86M | -$110M | -$360M |
| EPS (diluted) | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.54 | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
| Diluted shares | 16M | 26M | 58M | 72M | 73M | 77M | 77M | 94M | 109M | 113M |
Balance sheet
Fiscal years, from Viking Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $13M | $21M | $302M | $276M | $248M | $202M | $155M | $362M | $903M | $706M |
| Total current assets | $14M | $22M | $302M | $284M | $256M | $211M | $167M | $367M | $907M | $716M |
| Total assets | $15M | $22M | $302M | $284M | $257M | $211M | $169M | $368M | $908M | $716M |
| Total current liabilities | $6M | $9M | $5M | $7M | $12M | $9M | $22M | $19M | $27M | $77M |
| Total liabilities | $6M | $9M | $5M | $7M | $12M | $9M | $23M | $20M | $28M | $77M |
| Shareholders' equity | $8M | $13M | $298M | $277M | $244M | $202M | $145M | $348M | $880M | $639M |
| Net debt | -$3M | -$9M | -$25M | -$8M | -$29M | -$26M | -$37M | -$56M | -$27M | -$166M |
Cash flow
Fiscal years, from Viking Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11M | -$15M | -$19M | -$25M | -$22M | -$48M | -$48M | -$73M | -$88M | -$279M |
| Stock-based compensation | $2M | $1M | $3M | $4M | $6M | $6M | $9M | $17M | $30M | $41M |
| Share buybacks (net) | -$229 | — | — | — | — | — | -$7M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VKTX.
Open VKTX in InvestinglyQuestions
What was Viking Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
From Viking Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.